Abeona Therapeutics Inc

Abeona Therapeutics Inc a clinicalstage biopharmaceutical company develops gene and cell therapies for lifethreatening rare genetic diseases Its lead program is EB101 an autologous genecorrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa The company also develops ABO102 an adenoassociated virus AAVbased gene therapy for Sanfilippo syndrome type A ABO201 to treat CLN3 disease ABO401 for the treatment of cystic fibrosis and ABO50X for the treatment of genetic eye disorders In addition it is developing AAVbased gene therapy through its AIM vector platform programs The company was formerly known as PlasmaTech Biopharmaceuticals Inc and changed its name to Abeona Therapeutics Inc in June 2015 Abeona Therapeutics Inc was incorporated in 1974 and is headquartered in New York New York